Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience

Crvenkova, Simonida; Ivkovski, Lj; Dimovski, A; Kaeva, B

Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience

Journal

Prilozi

Date Issued

2012

Author(s)

Ivkovski, Lj

Dimovski, A

Kaeva, B

Abstract

The aim of this study was to evaluate tumour response, QoL and adverse effects of erlotinib, EGFR tyrosine kinase inhibitor (TKI), as a second line therapy for patients with EGFR mutation in NSCLC, after failure of previous first-line therapy.